New hope for lung cancer patients: drug may halt risky spots
NCT ID NCT05528458
First seen Apr 29, 2026 · Last updated May 12, 2026 · Updated 2 times
Summary
This study tests whether the drug osimertinib can stop or shrink small, hazy spots (called ground-glass nodules) in the lungs of people who have already had surgery for a type of lung cancer with a specific gene change (EGFR mutation). About 59 adults aged 30–75 will take one pill daily for up to 3 years. The goal is to see if the drug prevents these spots from turning into cancer, without needing more surgery or lifelong treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sehoon Lee
RECRUITINGSeoul, 06351, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.